The carcinoid tumor market was valued at USD 1.14 Billion in 2025. The market is expected to grow at a CAGR of 10.50% during the forecast period of 2026-2035, with the values likely to reach USD 3.09 Billion by 2035. The market growth is driven by The market is driven by rising incidences of neuroendocrine tumors and improved diagnostic accuracy through advanced imaging and biomarker testing. Increasing adoption of targeted drug therapies and immunotherapy for metastatic carcinoid tumors is expected to enhance treatment efficacy and patient survival, supporting strong market expansion during the forecast period.
Base Year
Historical Period
Forecast Period
Compound Annual Growth Rate
10.5%
Value in USD Billion
2026-2035
*this image is indicative*
Carcinoid tumor refers to a slow-growing cancerous mass of cells that can occur in several places throughout the body. These tumors usually originate in the digestive tract (stomach, small intestine, appendix, colon, or rectum) or the lungs. Carcinoid tumors fall under the category of neuroendocrine tumors and are commonly treated with the help of surgery and medications that block cancer cells from releasing hormones. Advancements in diagnostic techniques and the growing awareness among healthcare professionals are resulting in rising detection rates of carcinoid tumors, which is contributing to the market growth. The increasing aging population which is at a higher risk of developing carcinoid tumors further fuels the market demand. Moreover, the rising introduction of targeted therapies, significant investment in research and development, and the growth in clinical trials are some of the factors poised to impact the market dynamics.
Growth in Clinical Trials to Fuel Market Growth
In March 2024 , the findings of a clinical trial called NETTER-2 revealed that individuals with advanced neuroendocrine tumors (carcinoid tumors) in the digestive tract may benefit from a combination treatment that includes the drugs Lu 177-dotatate (Lutathera) and octreotide (Sandostatin). The data demonstrated that participants who took the combination therapy lived around 3 times longer without progression of their cancer than those who received octreotide alone. The growth in such clinical trials exploring the efficacy of new treatment combinations is expected to bolster the market demand in the forecast period.
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
"Carcinoid Tumor Market Report and Forecast 2026-2035" offers a detailed analysis of the market based on the following segments:
Market Breakup by Tumor Site
Market Breakup by Treatment Type
Market Breakup by End User
Market Breakup by Region
Market Segmentation Based on Tumor Site is Anticipated to Witness Substantial Growth
Based on the site of the tumor, the market is segmented into lung and gastrointestinal carcinoid tumors, among others. Lung carcinoid tumors refer to a type of neuroendocrine tumor that occurs in the lungs. These carcinoid tumors are treated with the help of surgery, chemotherapy, and targeted therapies. The rising innovations in surgical techniques, radiation therapy, and novel targeted therapies are expected to fuel the growth of this segment.
On the other hand, gastrointestinal carcinoid tumors usually occur in the digestive tract, including the stomach, small intestine, appendix, colon, and rectum. The high prevalence of gastrointestinal carcinoid tumors and the increasing advancements in minimally invasive surgical techniques are the key factors propelling the demand for this segment.
The market segmentation by region includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States covers a high market share due to the significant investments in research and development and the presence of a well-established healthcare system. The availability of advanced diagnostic tools such as PET/CT scans and MRI which facilitates early detection and monitoring of carcinoid tumors also supports the market growth in the region. Moreover, the rising healthcare expenditure and the growth in clinical trials investigating new treatment options are anticipated to aid market expansion.
The key features of the market report comprise patent analysis, grants analysis, clinical trial analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:
Global pharmaceutical giant Pfizer is focused on developing treatments in the oncology and rare disease domain. Pfizer's SUTENT® (sunitinib malate ), a tyrosine kinase inhibitor, is used to treat progressive, well-differentiated pancreatic neuroendocrine tumors or carcinoid tumors. The company's strong focus on developing next-generation therapies for cancer treatment is likely to help it maintain its leading market position.
Cadila Pharmaceuticals, headquartered in Gujarat, India, is a multinational pharmaceutical company known for its innovative and affordable treatment solutions across various therapeutic areas including oncology, cardiology, respiratory, and gastroenterology.
Eli Lilly and Company, headquartered in Indianapolis, Indiana, is one of the key players in the market with a robust pipeline of oncology products. Eli Lilly's anti-VEGFR 2 monoclonal antibody Ramucirumab is undergoing clinical development or the treatment of various cancers including carcinoid cancer. The company's investment in targeted therapies and immuno-oncology is anticipated to expand its market presence in the coming years.
F. Hoffmann-La Roche AG (Roche), a Swiss multinational holding healthcare company, plays a significant role in the growth of the market. It focuses on developing targeted therapies for cancer treatment, including rare diseases like carcinoid tumors. The company is engaged in exploring innovative oncology drugs that help to slow tumor growth by blocking certain pathways involved in the division of cancer cells.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include AstraZeneca and AbbVie Inc.
Upto 15% Off
USD
$3299 $2969
$5499 $4949
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Tumor Site |
|
| Breakup by Treatment Type |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share